Diagnosis of HDV: From virology to non-invasive markers of fibrosis

被引:2
作者
Majeed, Nehna Abdul [1 ]
Hitawala, Asif A. [1 ]
Heller, Theo [1 ]
Koh, Christopher [1 ,2 ]
机构
[1] Natl Inst Diabet & Digest & Kidney Dis, Liver Dis Branch, NIH, Bethesda, MD USA
[2] NIDDK, Liver Dis Branch, NIH, 10 Ctr Dr,CRC Bldg 10,RM 5 2551, Bethesda, MD 20892 USA
关键词
artificial intelligence; diagnostics; hepatitis delta; non-invasive fibrosis markers; virology; HEPATITIS-DELTA-VIRUS; POLYMERASE-CHAIN-REACTION; B SURFACE-ANTIGEN; TIME PCR ASSAY; LIVER FIBROSIS; ASPARTATE-AMINOTRANSFERASE; BULEVIRTIDE MONOTHERAPY; QUANTITATIVE DETECTION; PEGYLATED INTERFERON; D INFECTION;
D O I
10.1111/liv.15515
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis D viral infection in humans is a disease that requires the establishment of hepatitis B, relying on hepatitis B surface Ag and host cellular machinery to replicate and propagate the infection. Since its discovery in 1977, substantial progress has been made to better understand the hepatitis D viral life cycle, pathogenesis and modes of transmission along with expanding on clinical knowledge related to prevention, diagnosis, monitoring and treatment. The availability of serologic diagnostic assays for hepatitis D infection has evolved over time with current widespread availability, improved detection and standardized reporting. With human migration, the epidemiology of hepatitis D infection has changed over time. Thus, the ability to use diagnostic assays remains essential to monitor the global impact of hepatitis D infection. Separately, while liver biopsy remains the gold standard for the staging of this rapidly progressive and severe form of chronic viral hepatitis, there is an unmet need for clinical monitoring of chronic hepatitis D infection for management of progressive disease. Thus, exploration of the utility of non-invasive fibrosis markers in hepatitis D is ongoing. In this review, we discuss the virology, the evolution of diagnostics and the development of non-invasive markers for the detection and monitoring of fibrosis in patients with hepatitis D infection.
引用
收藏
页码:31 / 46
页数:16
相关论文
共 142 条
[1]   Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience [J].
Abbas, Zaigham ;
Memon, Mohammad S. ;
Mithani, Hammad ;
Jafri, Wasim ;
Hamid, Saeed .
ANTIVIRAL THERAPY, 2014, 19 (05) :463-468
[2]   Life cycle and pathogenesis of hepatitis D virus: A review [J].
Abbas, Zaigham ;
Afzal, Rafia .
WORLD JOURNAL OF HEPATOLOGY, 2013, 5 (12) :666-675
[3]   Myristoylation signal transfer from the large to the middle or the small HBV envelope protein leads to a loss of HDV particles infectivity [J].
Abou-Jaoude, Georges ;
Molina, Sonia ;
Maurel, Patrick ;
Sureau, Camille .
VIROLOGY, 2007, 365 (01) :204-209
[4]  
[Anonymous], 2020, EUROPEAN MED AGENCY
[5]   Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials [J].
Asif, Bilal ;
Koh, Christopher .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (09) :905-920
[6]   Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition [J].
Barrera, A ;
Guerra, B ;
Notvall, L ;
Lanford, RE .
JOURNAL OF VIROLOGY, 2005, 79 (15) :9786-9798
[7]   Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study [J].
Bazinet, M. ;
Pantea, V. ;
Cebotarescu, V. ;
Cojuhari, L. ;
Jimbei, P. ;
Vaillant, A. .
JOURNAL OF HEPATOLOGY, 2018, 68 :S509-S509
[8]   Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study [J].
Bogomolov, Pavel ;
Alexandrov, Alexander ;
Voronkova, Natalia ;
Macievich, Maria ;
Kokina, Ksenia ;
Petrachenkova, Maria ;
Lehr, Thorsten ;
Lempp, Florian A. ;
Wedemeyer, Heiner ;
Haag, Mathias ;
Schwab, Matthias ;
Haefeli, Walter E. ;
Blank, Antje ;
Urban, Stephan .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :490-498
[9]   HEPATITIS DELTA VIRUS - PROTEIN-COMPOSITION OF DELTA ANTIGEN AND ITS HEPATITIS-B VIRUS-DERIVED ENVELOPE [J].
BONINO, F ;
HEERMANN, KH ;
RIZZETTO, M ;
GERLICH, WH .
JOURNAL OF VIROLOGY, 1986, 58 (03) :945-950
[10]  
Bonn B, 2022, J HEPATOL, V77, pS843